Testosterone for Low Desire: What Evidence Supports
SaveTestosterone modestly raises sexual desire in postmenopausal women with distressing low libido and no other cause, adding about one satisfying sexual event every 4 weeks over placebo. No product is approved for women in most countries, so it is prescribed off-label at roughly one-tenth of male doses and monitored with blood tests.
Last updated: July 2026
What does the evidence actually show?
Testosterone has one well-supported use in women: treating hypoactive sexual desire disorder after menopause. A 2019 global consensus statement, based on a systematic review and endorsed by The Endocrine Society and the International Menopause Society, concluded that postmenopausal HSDD is the only indication with strong evidence 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months.. In the trials, testosterone added roughly one additional satisfying sexual event every 4 weeks compared with placebo — a genuine but modest effect 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months.. According to the American College of Obstetricians and Gynecologists, it may be considered for carefully selected women when other causes are ruled out 2Ref 2American College of Obstetricians and Gynecologists (2019).Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213.ACOG guidance that testosterone may be considered for carefully selected postmenopausal women with hypoactive sexual desire disorder once other causes are excluded, and that HSDD requires distress persisting at least 6 months.. Evidence does not support prescribing it for energy, mood, bone strength, or general well-being 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months..
Who is testosterone therapy actually for?
Testosterone therapy targets a narrow group: postmenopausal women with genuinely distressing low desire that persists at least 6 months despite addressing other factors 2Ref 2American College of Obstetricians and Gynecologists (2019).Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213.ACOG guidance that testosterone may be considered for carefully selected postmenopausal women with hypoactive sexual desire disorder once other causes are excluded, and that HSDD requires distress persisting at least 6 months.. When lab testing, medication review, relationship factors, and vaginal symptoms have all been considered, testosterone becomes a reasonable option to discuss 2Ref 2American College of Obstetricians and Gynecologists (2019).Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213.ACOG guidance that testosterone may be considered for carefully selected postmenopausal women with hypoactive sexual desire disorder once other causes are excluded, and that HSDD requires distress persisting at least 6 months.. The North American Menopause Society likewise restricts it to postmenopausal HSDD and advises against relying on blood testosterone levels to diagnose low desire 3Ref 3The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.The North American Menopause Society position restricting testosterone to postmenopausal HSDD and advising against using blood testosterone levels to diagnose low desire.. Evidence in premenopausal women is insufficient, so the global consensus does not endorse it before menopause 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months.. It is not a treatment for the natural, gradual decline in testosterone levels women see with age, which is not a disease. Many women first try lower-risk steps, such as easing dryness with vaginal moisturizers or estrogen or reviewing broader hormone therapy options 4Ref 4MedlinePlus (National Library of Medicine) (2026).Hormone Replacement Therapy.Patient-facing overview of menopausal hormone therapy options women may consider alongside or before testosterone..
How is it prescribed and monitored?
Because no female formulation is approved in most countries, clinicians prescribe testosterone off-label, typically using a small fraction of a male product. The global consensus advises dosing to keep blood testosterone within the normal premenopausal range — roughly one-tenth of typical male doses — and checking levels before and during treatment to avoid excess 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months.. Monitoring matters because too much testosterone can cause acne, unwanted hair growth, or voice changes. According to the same statement, levels above the female range offer no added benefit, and non-genital signs of excess should prompt a dose review 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months.. Compounded pellets and injections often deliver unpredictable, supraphysiologic amounts and are not recommended 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months..
What are the risks and unknowns?
Short-term testosterone therapy appears reasonably safe in the studied doses, but the long-term picture is genuinely uncertain. The global consensus notes that safety data beyond about 24 months are limited, and effects on the breast, heart, and blood vessels over many years are not established 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months.. Common, dose-related side effects include acne and extra facial or body hair, which usually reverse if the dose is lowered 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months.. A Cochrane review of hormone therapy for sexual function found only small benefits overall, a reminder that no hormone reliably restores desire for everyone 5Ref 5Nastri CO, Lara LA, Ferriani RA, et al. (2013).Hormone therapy for sexual function in perimenopausal and postmenopausal women.Systematic review finding only small overall benefits of hormone therapy on sexual function, underscoring that no hormone reliably restores desire for everyone.. Oral testosterone is avoided because of effects on cholesterol and the liver, so non-oral routes are preferred 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months..
When testosterone for low desire needs a specialist
Testosterone therapy for low desire calls for a clinician comfortable with off-label menopause care. According to the global consensus, the decision belongs with a professional who can confirm postmenopausal HSDD, rule out other causes, choose a physiologic dose, and monitor blood levels over time 1Ref 1Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019).Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months.. A menopause specialist or gynecologist is best placed to weigh the modest benefit against the unknowns and to stop treatment if it is not helping within a few months 2Ref 2American College of Obstetricians and Gynecologists (2019).Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213.ACOG guidance that testosterone may be considered for carefully selected postmenopausal women with hypoactive sexual desire disorder once other causes are excluded, and that HSDD requires distress persisting at least 6 months.. Because desire has many inputs, the conversation should also cover sleep, mood, medications, relationship factors, and when low desire is worth a medical visit. Gale can help you prepare for that conversation.
Common questions
Related
Sexual health
Vyleesi (Bremelanotide): An On-Demand OptionSexual health
Libido Supplements: What's Actually in ThemSexual health
HRT and Libido: What It Can and Can't Fix
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
Signs testosterone needs closer review
- —New acne, a deepening voice, or noticeable facial or body hair while using testosterone is a reason to seek prompt clinician review of your dose.
- —No improvement in desire after a few months of appropriately dosed therapy is a reason to revisit the plan with your clinician rather than raise the dose on your own.
- —Low desire alongside persistent sadness or loss of interest in everything is a reason to seek clinician review; if thoughts of self-harm arise, call or text 988.
- —Using compounded testosterone pellets or high-strength products is a reason to seek review, because these can push levels well above the normal female range.
This article is general health education, not medical advice or a prescription. Whether testosterone is appropriate is a decision to make with a menopause specialist or gynecologist who can confirm the diagnosis and monitor treatment.
References
- 1.Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019). Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism. doi:10.1210/jc.2019-01603 ✓Global consensus that postmenopausal HSDD is the only evidence-based indication for testosterone in women; benefit of roughly one additional satisfying sexual event every 4 weeks; off-label use at physiologic premenopausal-range doses (about one-tenth of male doses) with blood-level monitoring; no established benefit for energy, mood, or bone and limited long-term safety data beyond about 24 months.
- 2.American College of Obstetricians and Gynecologists (2019). Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000003324 ✓ACOG guidance that testosterone may be considered for carefully selected postmenopausal women with hypoactive sexual desire disorder once other causes are excluded, and that HSDD requires distress persisting at least 6 months.
- 3.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓The North American Menopause Society position restricting testosterone to postmenopausal HSDD and advising against using blood testosterone levels to diagnose low desire.
- 4.MedlinePlus (National Library of Medicine) (2026). Hormone Replacement Therapy. MedlinePlus, U.S. National Library of Medicine (NIH). link ✓Patient-facing overview of menopausal hormone therapy options women may consider alongside or before testosterone.
- 5.Nastri CO, Lara LA, Ferriani RA, et al. (2013). Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD009672.pub2 ✓Systematic review finding only small overall benefits of hormone therapy on sexual function, underscoring that no hormone reliably restores desire for everyone.
5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy